• Vaccine Name: BG-Lentinan
• Target Pathogen: Mycobacterium tuberculosis
• Target Disease: Tuberculosis
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: Rabbit
• Antigen: Fusion protein BG, composed by BfrB and GrpE from Mycobacterium tuberculosis (Zhou et al., 2025).
• bfrB gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation (Zhou et al., 2025).
  • Detailed Gene Information: Click Here.
• grpE gene engineering:
  • Type: Fusion Protein
  • Description: Use in prepare fusion protein (Zhou et al., 2025).
  • Detailed Gene Information: Click Here.
• Preparation: BG fusion protein expressed in E. coli BL21, purified by ammonium sulfate precipitation and hydrophobic interaction chromatography. Mixed with lentinan and Phosphate-Buffered Saline (Zhou et al., 2025).
• Immunization Route: subcutaneous injection
• Description: BG–Lentinan is a fusion protein subunit vaccine composed of the BfrB–GrpE fusion protein formulated with lentinan as an adjuvant, which induces strong antigen-specific IgG responses and provides effective protection by significantly reducing bacterial burden in infected tissues (Zhou et al., 2025).

Rabbit Response

• Host gender: female
• Vaccination Protocol: Rabbits were immunized subcutaneously with BG–Lentinan at weeks 0, 2, and 4, receiving 1000 µL per dose containing 100 µg of BG fusion protein and 500 µg of lentinan (Zhou et al., 2025).
• Immune Response: BG–Lentinan vaccination significantly increased BfrB- and GrpE-specific IgG levels in rabbit serum measured six weeks after the final immunization (Zhou et al., 2025).
• Challenge Protocol: Six weeks after the final immunization, rabbits were challenged intradermally in the dorsal skin with 5 × 10⁶ CFU of Mycobacterium bovis BCG in a 100 µL volume (Zhou et al., 2025).
• Efficacy: The BG–Lentinan vaccine significantly reduced bacterial load in skin lesions and showed the strongest protective efficacy among all tested groups (Zhou et al., 2025).